X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs WOCKHARDT LTD. - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA WOCKHARDT LTD. ABBOTT INDIA/
WOCKHARDT LTD.
 
P/E (TTM) x 37.1 -19.2 - View Chart
P/BV x 9.5 2.0 468.1% View Chart
Dividend Yield % 0.7 0.0 38,230.4%  

Financials

 ABBOTT INDIA   WOCKHARDT LTD.
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
WOCKHARDT LTD.
Mar-18
ABBOTT INDIA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs6,1101,012 603.8%   
Low Rs3,996532 751.8%   
Sales per share (Unadj.) Rs1,552.2355.9 436.2%  
Earnings per share (Unadj.) Rs188.8-60.3 -313.2%  
Cash flow per share (Unadj.) Rs196.4-46.8 -420.1%  
Dividends per share (Unadj.) Rs55.000.01 550,000.0%  
Dividend yield (eoy) %1.10 84,002.1%  
Book value per share (Unadj.) Rs796.6257.8 309.0%  
Shares outstanding (eoy) m21.25110.63 19.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.32.2 150.1%   
Avg P/E ratio x26.8-12.8 -209.0%  
P/CF ratio (eoy) x25.7-16.5 -155.9%  
Price / Book Value ratio x6.33.0 211.9%  
Dividend payout %29.10 -175,592.2%   
Avg Mkt Cap Rs m107,37685,379 125.8%   
No. of employees `0003.36.3 53.1%   
Total wages/salary Rs m3,9379,371 42.0%   
Avg. sales/employee Rs Th9,929.36,295.0 157.7%   
Avg. wages/employee Rs Th1,185.11,498.3 79.1%   
Avg. net profit/employee Rs Th1,207.7-1,066.3 -113.3%   
INCOME DATA
Net Sales Rs m32,98539,369 83.8%  
Other income Rs m1,1701,202 97.3%   
Total revenues Rs m34,15540,571 84.2%   
Gross profit Rs m5,24518 28,661.2%  
Depreciation Rs m1621,495 10.8%   
Interest Rs m382,555 1.5%   
Profit before tax Rs m6,215-2,830 -219.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m2,203257 857.1%   
Profit after tax Rs m4,012-6,669 -60.2%  
Gross profit margin %15.90 34,208.3%  
Effective tax rate %35.4-9.1 -390.2%   
Net profit margin %12.2-16.9 -71.8%  
BALANCE SHEET DATA
Current assets Rs m22,65533,796 67.0%   
Current liabilities Rs m6,68126,917 24.8%   
Net working cap to sales %48.417.5 277.2%  
Current ratio x3.41.3 270.1%  
Inventory Days Days6579 81.6%  
Debtors Days Days2989 32.7%  
Net fixed assets Rs m83539,664 2.1%   
Share capital Rs m213553 38.4%   
"Free" reserves Rs m16,71527,968 59.8%   
Net worth Rs m16,92828,522 59.4%   
Long term debt Rs m021,731 0.0%   
Total assets Rs m24,16281,620 29.6%  
Interest coverage x163.7-0.1 -152,244.0%   
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x1.40.5 283.0%   
Return on assets %16.8-5.0 -332.6%  
Return on equity %23.7-23.4 -101.4%  
Return on capital %36.9-7.7 -481.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3699,807 3.8%   
Fx outflow Rs m3,8071,789 212.8%   
Net fx Rs m-3,4388,019 -42.9%   
CASH FLOW
From Operations Rs m1,527684 223.1%  
From Investments Rs m-2,1486,302 -34.1%  
From Financial Activity Rs m-1,024-7,695 13.3%  
Net Cashflow Rs m-1,646-664 247.8%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 2.3 343.5%  
FIIs % 0.1 7.7 1.3%  
ADR/GDR % 0.0 0.1 -  
Free float % 17.1 15.4 111.0%  
Shareholders   18,270 67,757 27.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   CIPLA  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  PIRAMAL ENTERPRISES  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Nov 14, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS